Cargando…
Immunotherapeutic Strategies in the Management of Osteosarcoma
Osteosarcoma (OS) is the most common primary malignant bone cancer with a high tendency for metastasis. Although treatment strategies involving surgery and chemotherapy have improved outcomes for patients with OS, the prognosis of recurrent OS is quite unsatisfactory. Primary reasons leading to mort...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018813/ https://www.ncbi.nlm.nih.gov/pubmed/36937115 http://dx.doi.org/10.26502/josm.511500076 |
_version_ | 1784907890509742080 |
---|---|
author | Supra, Rajiv Agrawal, Devendra K |
author_facet | Supra, Rajiv Agrawal, Devendra K |
author_sort | Supra, Rajiv |
collection | PubMed |
description | Osteosarcoma (OS) is the most common primary malignant bone cancer with a high tendency for metastasis. Although treatment strategies involving surgery and chemotherapy have improved outcomes for patients with OS, the prognosis of recurrent OS is quite unsatisfactory. Primary reasons leading to mortality in OS patients are resistance to currently used therapies and the subsequent lung metastasis. Immunotherapy, however, has been shown to be a promising therapeutic strategy against OS. As research progresses, immunotherapy is gradually becoming irreplaceable. This article provides a critical evaluation of several therapeutic strategies for OS including immunomodulation, vaccine therapy, and immunologic checkpoint blockade. |
format | Online Article Text |
id | pubmed-10018813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-100188132023-03-16 Immunotherapeutic Strategies in the Management of Osteosarcoma Supra, Rajiv Agrawal, Devendra K J Orthop Sports Med Article Osteosarcoma (OS) is the most common primary malignant bone cancer with a high tendency for metastasis. Although treatment strategies involving surgery and chemotherapy have improved outcomes for patients with OS, the prognosis of recurrent OS is quite unsatisfactory. Primary reasons leading to mortality in OS patients are resistance to currently used therapies and the subsequent lung metastasis. Immunotherapy, however, has been shown to be a promising therapeutic strategy against OS. As research progresses, immunotherapy is gradually becoming irreplaceable. This article provides a critical evaluation of several therapeutic strategies for OS including immunomodulation, vaccine therapy, and immunologic checkpoint blockade. 2023 2023-02-06 /pmc/articles/PMC10018813/ /pubmed/36937115 http://dx.doi.org/10.26502/josm.511500076 Text en https://creativecommons.org/licenses/by/4.0/This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license 4.0 |
spellingShingle | Article Supra, Rajiv Agrawal, Devendra K Immunotherapeutic Strategies in the Management of Osteosarcoma |
title | Immunotherapeutic Strategies in the Management of Osteosarcoma |
title_full | Immunotherapeutic Strategies in the Management of Osteosarcoma |
title_fullStr | Immunotherapeutic Strategies in the Management of Osteosarcoma |
title_full_unstemmed | Immunotherapeutic Strategies in the Management of Osteosarcoma |
title_short | Immunotherapeutic Strategies in the Management of Osteosarcoma |
title_sort | immunotherapeutic strategies in the management of osteosarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018813/ https://www.ncbi.nlm.nih.gov/pubmed/36937115 http://dx.doi.org/10.26502/josm.511500076 |
work_keys_str_mv | AT suprarajiv immunotherapeuticstrategiesinthemanagementofosteosarcoma AT agrawaldevendrak immunotherapeuticstrategiesinthemanagementofosteosarcoma |